Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy

doi:10.4254/wjh.v7.i15.1964

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 15

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11908)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

700

WORD

345

HTML

7898

Tables (1-1)

224

Sum=9167

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1049

Download

1692

Sum=2741

Jul 28, 2015 (publication date) through Jan 6, 2025

Times Cited of This Article

Times Cited (98)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Jul 28, 2015; 7(15): 1964-1970
Published online Jul 28, 2015. doi: 10.4254/wjh.v7.i15.1964

Table 1 Molecular targets and potential therapeutic agents for hepatocellular carcinoma

Molecular targets	Therapeutic agents	Phase study	Mechanism of action
VEGF/VEGFR	Bebacizumab	II	Anti-angiogenic
	Vatalanib (PTK787)	I-II
	Cediranib (AZD2171)
	Brivanib
	Sunitinib	II-III
	Linifanib (ABT869)
	Ramucirumab
EGFR/ErbB1/Her1	Cetuximab		EGFR inhibitor
EGFR/ErbB1/Her1	Erlotinib	III
EGFR/ErbB1/Her1	Gefitinib	I-II
EGFR/ErbB1/Her1 and ErbB2/Her2/Neu	Lapatinib
IGF/IGFR	OSI-906
	IMC-A12
	AVE1642
	BIIB922
Ras/Raf/MEK/ERK	Sorafenib	III	Multi-kinase inhibitor
PI3K/Akt/mTOR	AZD8055		mTOR inhibitor
	Everolimus	III
	Sirolimus	I-II
	Temsirolimus
Wnt-β-catenin	PFK118-310
	PFK115-584
	CGP049090
MET	Tivanitib	II	HGF/c-MET inhibitor
HSP-90	STA-9090	I-II	HSP-90 inhibitor

VEGFR: Vascular endothelial growth factor receptor; EGFR: Endothelial growth factor receptor; IGF: Insulin-like growth factor; mTOR: Mammalian target of rapamycin; MET: MNNG HOS transforming gene; HGF: Hepatocyte growth factor; HSP: Heat shock protein; STA-9090: Ganetespib, Hsp90 inhibitor.

Citation: Chen C, Wang G. Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy. World J Hepatol 2015; 7(15): 1964-1970
URL: https://www.wjgnet.com/1948-5182/full/v7/i15/1964.htm
DOI: https://dx.doi.org/10.4254/wjh.v7.i15.1964